A Phase 2 Study of Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2017
At a glance
- Drugs Tipifarnib (Primary)
- Indications Chronic myelomonocytic leukaemia
- Focus Therapeutic Use
- Sponsors Kura Oncology
- 14 Mar 2017 According to a Kura Oncology media release, data expected during the first half of 2018.
- 17 Jan 2017 According to Kura Oncology media release, first patient has been dosed in this study.
- 20 Oct 2016 Status changed from not yet recruiting to recruiting.